Charles Dumontet

Dr. Charles Dumontet


Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2017 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
ABAlain Beck
Alain Beck
LGLiliane Goetsch
Liliane Goetsch
CDCharles Dumontet
Charles Dumontet
NCNathalie Corvaïa
Nathalie Corvaïa

1 October 2010 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
CDCharles Dumontet
Charles Dumontet
MJMary Ann Jordan
Mary Ann Jordan

31 May 2013 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
LJLars Petter Jordheim
Lars Petter Jordheim
DDDavid Durantel
David Durantel
Fabien ZoulimFabien Zoulim
Fabien Zoulim
CDCharles Dumontet
Charles Dumontet

10 May 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MAMichel Attal
Michel Attal
VLValerie Lauwers-Cances
Valerie Lauwers-Cances
GMGerald Marit
Gerald Marit
DCDenis Caillot
Denis Caillot
PMPhilippe Moreau
Philippe Moreau
IIIFM Investigators
IFM Investigators
High-dose chemotherapy with autologous stem-cell transplantation is a standard treatment for young patients with multiple myeloma. Residual disease is almost always present after transplantation and is responsible for relapse. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide maintenance therapy after transplantation.

12 June 2023 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
CDCharles Dumontet
Charles Dumontet
JRJanice M. Reichert
Janice M. Reichert
PSPeter D. Senter
Peter D. Senter
JLJohn M. Lambert
John M. Lambert
ABAlain Beck
Alain Beck

5 January 2007 in Blood
Verified
Journal Article
Closed access
HAHervé Avet-Loiseau
Hervé Avet-Loiseau
MAMichel Attal
Michel Attal
PMPhilippe Moreau
Philippe Moreau
CCCatherine Charbonnel
Catherine Charbonnel
FGFrédÉrIc Garban
FrédÉrIc Garban
CMClaire Mathiot
Claire Mathiot
Acquired genomic aberrations have been shown to significantly impact survival in several hematologic malignancies. We analyzed the prognostic value of the most frequent chromosomal changes in a large series of patients with newly diagnosed symptomatic myeloma prospectively enrolled in homogeneous therapeutic trials. All the 1064 patients enrolled in the IFM99 trials conducted by the Intergroupe Francophone du Myélome benefited from an interphase fluorescence in situ hybridization analysis performed on purified bone marrow plasma cells. They were systematically screened for the following genomic aberrations: del(13), t(11;14), t(4;14), hyperdiploidy, MYC translocations, and del(17p). Chromosomal changes were observed in 90% of the patients. The del(13), t(11;14), t(4;14), hyperdiploidy, MYC translocations, and del(17p) were present in 48%, 21%, 14%, 39%, 13%, and 11% of the patients, respectively. After a median follow-up of 41 months, univariate statistical analyses revealed that del(13), t(4;14), nonhyperdiploidy, and del(17p) negatively impacted both the event-free survival and the overall survival, whereas t(11;14) and MYC translocations did not influence the prognosis. Multivariate analyses on 513 patients annotated for all the parameters showed that only t(4;14) and del(17p) retained prognostic value for both the event-free and overall survivals. When compared with the currently used International Staging System, this prognostic model compares favorably. In myeloma, the genomic aberrations t(4;14) and del(17p), together with β2-microglobulin level, are important independent predictors of survival. These findings have implications for the design of risk-adapted treatment strategies.